Press coverage about Marrone Bio Innovations (NASDAQ:MBII) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Marrone Bio Innovations earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned press coverage about the basic materials company an impact score of 46.780914741872 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

MBII has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating on shares of Marrone Bio Innovations in a report on Friday, May 12th. ValuEngine upgraded shares of Marrone Bio Innovations from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Piper Jaffray Companies set a $1.00 price objective on shares of Marrone Bio Innovations and gave the stock a “hold” rating in a report on Saturday, July 22nd. Zacks Investment Research upgraded shares of Marrone Bio Innovations from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $2.50 target price on shares of Marrone Bio Innovations in a research note on Tuesday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. Marrone Bio Innovations has an average rating of “Hold” and an average target price of $2.50.

Marrone Bio Innovations (NASDAQ MBII) traded up 14.30% during trading on Friday, hitting $1.20. 551,416 shares of the stock traded hands. The company’s market cap is $37.62 million. The firm has a 50-day moving average price of $1.12 and a 200 day moving average price of $1.50. Marrone Bio Innovations has a 52-week low of $0.85 and a 52-week high of $2.79.

Marrone Bio Innovations (NASDAQ:MBII) last released its earnings results on Monday, August 14th. The basic materials company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by $0.04. The company had revenue of $6.48 million during the quarter, compared to analysts’ expectations of $6.62 million. On average, equities analysts expect that Marrone Bio Innovations will post ($1.01) EPS for the current year.

WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Marrone Bio Innovations (MBII) Share Price” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/26/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-marrone-bio-innovations-mbii-share-price.html.

Marrone Bio Innovations Company Profile

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

Insider Buying and Selling by Quarter for Marrone Bio Innovations (NASDAQ:MBII)

Receive News & Stock Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related stocks with our FREE daily email newsletter.